The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...

Boehringer Ingelheim has announced an increase in ... Overall the company’s human pharmaceuticals business grew by 5.1%, with increasing sales from newer drugs offsetting the impact of expiring ...

By Andrew Pollack Hikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. Boehringer Ingelheim said ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

This year’s honorees, Boehringer Ingelheim and GSK, have set new standards in sustainable manufacturing. Boehringer Ingelheim’s team created a highly efficient 3-step synthesis for Spiroketone CD 7659 ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...